Literature DB >> 33495153

Correspondence on 'A pilot study of tofacitinib for refractory Behçet's syndrome'.

Jun Zou1, Chen-Hong Lin1, Yan Wang2, Yan Shen1, Jian-Long Guan3.   

Abstract

Entities:  

Keywords:  Behcet syndrome; biological therapy; patient reported outcome measures

Year:  2021        PMID： 33495153     DOI： 10.1136/annrheumdis-2020-219810

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  4 in total

1.  Extended-release tofacitinib for refractory Behçet disease: A case report.

Authors:  Chrong-Reen Wang; Tak-Wah Wong; Sheng-Min Hsu
Journal:  Medicine (Baltimore)       Date:  2022-04-15       Impact factor: 1.817

Review 2.  Behçet uveitis: Current practice and future perspectives.

Authors:  Shereen H Aboul Naga; Lameece Moustafa Hassan; Radwa T El Zanaty; Mohammad Refaat; Rana H Amin; Gaafar Ragab; Mahmoud M Soliman
Journal:  Front Med (Lausanne)       Date:  2022-09-07

3.  Tofacitinib as an alternative therapy for refractory intestinal Behçet's syndrome.

Authors:  Jun Zou; Jian-Fei Cai; Jing-Fen Ye; Jian-Long Guan
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-09-22       Impact factor: 3.625

Review 4.  Case report: Refractory intestinal Behçet's syndrome successfully treated with tofacitinib: A report of four cases.

Authors:  Na Zhao; Yanchun Tang; Shaokun Wang; Liping Cui; Xuehui Sun; Zhihua Wang; Ying Liu
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.